Kantar Health Blog

  • Mark Sales
    If you are still focused on whether a customer experience program will bring value to your organization, you are missing the point.
    Continue Reading > | Go comment! | Share
  • Crowd surfing: Competition in myeloma continues to rage on

    by Stephanie Hawthorne | Jun 2, 2015
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- The number of agents available to treat relapsed/refractory myeloma has expanded rapidly over the past three years, with the launch of next-generation proteasome inhibitor Kyprolis® (carfilzomib, Onyx /Amgen, accelerated FDA approval July 2012) and the next-generation immunomodulator Pomalyst® (pomalidomide, Celgene, FDA approved February 2013) as monotherapies, and the HDAC inhibitor Farydak® (panobinostat, Novartis, accelerated FDA approval February 2015) for use in combination with bortezomib + dexamethasone (VelDex). These three agents add to the long-established standards of care, Velcade® (bortezomib, Millennium/Takeda) and Revlimid® (lenalidomide, Celgene), which are used in both newly diagnosed and relapsed/refractory patients.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: ASCO 2015 --- Immunotherapy has dominated the conversation in oncology for the past several years, and the excitement still hasn’t waned at all - in fact it continues to grow. New drugs have entered development in this space, new mechanisms of action have emerged, and new tumor types have entered the focus of our attention. We have previously seen various level of evidence to support the activity of checkpoint inhibitors in melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, breast cancer, gastric cancer, head and neck cancer, and Hodgkin’s lymphoma. At this year’s annual meeting of the American Society of Clinical Oncology, we observed first reports of the activity of several PD-1 and PD-L1 inhibitors in multiple new tumor indications, adding to the growing body of evidence that suggests immunotherapy is closely approaching panacea status.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- In several B-cell malignancies, physicians have a number of new options for their patients, allowing these patients the promise of being treated for several lines of therapy. For chronic lymphocytic leukemia (CLL) and indolent lymphoma patients, physicians now have the option to use kinase inhibitors such as Imbruvica® (ibrutinib, Pharmacyclics/Janssen) or Zydelig® (idelalisib, Gilead). For multiple myeloma patients, physicians now have the option to utilize Kyprolis® (carfilzomib, Amgen/Onyx) or Pomalyst® (pomalidomide, Celgene).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- Rituxan® (rituximab, Roche/Genentech) forms the backbone of virtually every aspect of therapeutic management for B-cell non-Hodgkin’s Lymphoma (NHL); however, while clinically effective, approximately 20% of patients with indolent NHL (iNHL) are considered Rituxan-refractory. This poses an unmet need for patients, leaving them historically with only chemotherapy as a treatment option.
    Continue Reading > | Go comment! | Share